Phosphatidylserine vs Vinpocetine

Mechanism

Major phospholipid component of neuronal cell membranes (15-20% of total phospholipid pool) that maintains membrane fluidity and supports signal transduction. Serves as a cofactor for protein kinase C (PKC), Na+/K+-ATPase, and other membrane-bound enzymes critical for neurotransmitter release. Blunts HPA axis hyperactivation by modulating corticotrophin-releasing factor (CRF) receptor interactions, attenuating cortisol release during physical and psychological stress. Facilitates acetylcholine, dopamine, and norepinephrine release, and enhances glucose metabolism in the brain.

Standard Dosing

100-300mg daily

Timing

With meals (fat-containing preferred for absorption). Can be taken morning or evening. Cortisol-blunting effects are relevant for evening/pre-bed dosing in stressed individuals.

Cycle Duration

Ongoing; no cycling required. Clinical benefits observed from 6-12 weeks.

Side Effects

• Mild GI upset at high doses
• Insomnia (if taken too late in some individuals)
• Rare: nausea
• GI distress (uncommon)
• Insomnia (at higher doses)
• Headache (rare)

Contraindications

• Soy allergy (if soy-derived — use sunflower-derived instead)
• Known soy allergy (soy-derived PS)
• Antiphospholipid syndrome (theoretical concern)

Best Stacking Partners

Mechanism

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Standard Dosing

5-20 mg 2-3 times daily (15-60 mg/day total)

Timing

With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Side Effects

• Flushing
• GI distress
• Headache
• Dizziness
• Transient hypotension
• Sleep disturbance

Contraindications

• Severe hepatic impairment
• Pregnancy and lactation (FDA issued warning in 2019)
• Severe cardiac arrhythmias
• Recent hemorrhagic stroke

Best Stacking Partners